PL2206719T3 - Kompozycja farmaceutyczna zawierająca 3-beta-hydroksy-17-(1-h-benzimidazol-1-il)androsta-5,16-dien - Google Patents

Kompozycja farmaceutyczna zawierająca 3-beta-hydroksy-17-(1-h-benzimidazol-1-il)androsta-5,16-dien

Info

Publication number
PL2206719T3
PL2206719T3 PL10150763T PL10150763T PL2206719T3 PL 2206719 T3 PL2206719 T3 PL 2206719T3 PL 10150763 T PL10150763 T PL 10150763T PL 10150763 T PL10150763 T PL 10150763T PL 2206719 T3 PL2206719 T3 PL 2206719T3
Authority
PL
Poland
Prior art keywords
diene
methods
androsta
benzimidazole
beta
Prior art date
Application number
PL10150763T
Other languages
English (en)
Inventor
Angela Brodie
Vincent Njar
Original Assignee
Univ Maryland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Maryland filed Critical Univ Maryland
Publication of PL2206719T3 publication Critical patent/PL2206719T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL10150763T 2005-03-02 2006-03-02 Kompozycja farmaceutyczna zawierająca 3-beta-hydroksy-17-(1-h-benzimidazol-1-il)androsta-5,16-dien PL2206719T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US65739005P 2005-03-02 2005-03-02
EP06736460A EP1853619B1 (en) 2005-03-02 2006-03-02 3-beta-hydroxy-17-(1h-benzimidazol-1-yl)androsta-5,16-diene for use in the treatment of a prostate disease
EP10150763.0A EP2206719B1 (en) 2005-03-02 2006-03-02 Pharmaceutical composition comprising 3-beta-hydroxy-17-(1-h-benzimidazole-1-yl)androsta-5,16-diene

Publications (1)

Publication Number Publication Date
PL2206719T3 true PL2206719T3 (pl) 2015-03-31

Family

ID=36941503

Family Applications (2)

Application Number Title Priority Date Filing Date
PL10150763T PL2206719T3 (pl) 2005-03-02 2006-03-02 Kompozycja farmaceutyczna zawierająca 3-beta-hydroksy-17-(1-h-benzimidazol-1-il)androsta-5,16-dien
PL06736460T PL1853619T3 (pl) 2005-03-02 2006-03-02 3-beta-Hydroksy-17-(1H-benzimidazol-1-ilo)-androsta-5,16-dien do zastosowania do leczenia choroby prostaty

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL06736460T PL1853619T3 (pl) 2005-03-02 2006-03-02 3-beta-Hydroksy-17-(1H-benzimidazol-1-ilo)-androsta-5,16-dien do zastosowania do leczenia choroby prostaty

Country Status (22)

Country Link
US (1) US7875599B2 (pl)
EP (2) EP2206719B1 (pl)
JP (2) JP5130453B2 (pl)
KR (1) KR101380959B1 (pl)
CN (2) CN103349664A (pl)
AT (1) ATE482969T1 (pl)
AU (1) AU2006218711B2 (pl)
BR (1) BRPI0607523A2 (pl)
CA (1) CA2599953C (pl)
DE (1) DE602006017175D1 (pl)
DK (2) DK2206719T3 (pl)
EA (1) EA019560B1 (pl)
ES (2) ES2353413T3 (pl)
HK (1) HK1115387A1 (pl)
IL (3) IL185608A (pl)
MX (1) MX2007010593A (pl)
NZ (1) NZ561571A (pl)
PL (2) PL2206719T3 (pl)
PT (2) PT2206719E (pl)
SI (2) SI1853619T1 (pl)
WO (1) WO2006093993A1 (pl)
ZA (1) ZA200708106B (pl)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8569275B2 (en) 2002-08-28 2013-10-29 Harbor Therapeutics, Inc. Steroids having 7-oxgen and 17-heteroaryl substitution
DK2206719T3 (en) 2005-03-02 2015-01-26 Univ Maryland A pharmaceutical composition comprising 3-BETA-HYDROXY-17- (1-H-benzimidazol-1-yl) androsta-5, 16-DIEN
US8110550B2 (en) 2007-06-06 2012-02-07 University Of Maryland, Baltimore HDAC inhibitors and hormone targeted drugs for the treatment of cancer
US20110105445A1 (en) * 2008-03-12 2011-05-05 University Of Maryland, Baltimore Androgen receptor inactivation contributes to antitumor efficacy of cyp17 inhibitors in prostate cancer
US20100048913A1 (en) 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
US20110118219A1 (en) * 2008-03-25 2011-05-19 University Of Maryland, Baltimore Novel prodrugs of c-17-heteroaryl steroidal cyp17 inhibitors/antiandrogens: synthesis, in vitro biological activities, pharmacokinetics and antitumor activity
WO2009129208A2 (en) * 2008-04-14 2009-10-22 University Of Maryland, Baltimore Compositions and methods of inducing endoplasmic reticulum stress reponse
WO2010024930A2 (en) 2008-08-28 2010-03-04 President And Fellows Of Harvard College Cortistatin analogues and syntheses therof
AU2009320250A1 (en) * 2008-10-28 2010-06-03 Biomarin Pharmaceutical Inc. Decahydro-1H-indenoquinolinone and decahydro-3H-cyclopentaphenanthridinone CYP17 inhibitors
US20110319369A1 (en) * 2009-02-05 2011-12-29 Tokai Pharmaceuticals, Inc. Combination of a 17 alpha-hydroxylase/c17, 20-lyase inhibitor with an additional therapeutic agent
GB2479693B (en) * 2009-02-05 2014-04-09 Tokai Pharmaceuticals Inc Steroidal CYP17 inhibitors and their use in the treatment of cancer and prostate hyperplasia
EP3023433A1 (en) 2009-02-05 2016-05-25 Tokai Pharmaceuticals, Inc. Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens
GEP20156250B (en) 2009-06-26 2015-02-25 Novartis Ag 1,3-disubstituted imidazolidin-2-one derivatives as inhibitors of cyp 17
AU2010279398A1 (en) * 2009-08-07 2012-03-08 Tokai Pharmaceuticals, Inc. Treatment of prostate cancer
WO2011059969A2 (en) * 2009-11-13 2011-05-19 Tokai Pharmaceuticals, Inc. Mammalian metabolites of steroids
EP2506855A4 (en) * 2009-11-30 2014-07-30 Harbor Biosciences Inc ANTICARCINOMA COMPOUNDS AND SCREENING METHODS
EP2627648A1 (en) 2010-09-16 2013-08-21 Novartis AG 17aHYDROXYLASE/C17,20-LYASE INHIBITORS
TW201307378A (zh) * 2010-12-16 2013-02-16 Biomarin Pharm Inc Ｃｙｐ１１ｂ、ｃｙｐ１７及／或ｃｙｐ２１抑制劑
ES2656218T3 (es) 2011-04-28 2018-02-26 Novartis Ag Inhibidores de 17 alfa-hidroxilasa/C17,20-liasa
CA2841960A1 (en) * 2011-07-18 2013-01-24 Tokai Pharmaceuticals, Inc. Novel compositions and methods for treating prostate cancer
JP2015503508A (ja) * 2011-12-22 2015-02-02 トーカイ ファーマシューティカルズ，インク． ＰＩ３Ｋ／ｍＴＯＲ阻害剤を使用する併用療法のための方法および組成物
CA2904170A1 (en) 2013-03-14 2014-09-25 University Of Maryland, Baltimore Androgen receptor down-regulating agents and uses thereof
US9694005B2 (en) 2013-04-04 2017-07-04 University Of Maryland, Baltimore Nonsteroidal and steroidal compounds with potent androgen receptor down-regulation and anti prostate cancer activity
KR20160058774A (ko) 2013-08-12 2016-05-25 토카이 파마슈티컬, 아이엔씨. 안드로겐-표적 치료제를 이용하는 종양 질환 치료를 위한 바이오마커
EA201891279A1 (ru) 2013-12-24 2019-01-31 Президент Энд Феллоус Оф Гарвард Колледж Аналоги кортистатина, их синтез и применения
CN103694299A (zh) * 2014-01-13 2014-04-02 中国药科大学 甾体类雄激素受体抑制剂、其制备方法及其医药用途
WO2016119742A1 (zh) * 2015-01-29 2016-08-04 苏州晶云药物科技有限公司 (3β)-17-(1H-苯并咪唑-1-基)雄甾-5，16-二烯-3-醇的盐及其制备方法
EP3294298A4 (en) 2015-05-08 2018-10-17 President and Fellows of Harvard College Cortistatin analogues, syntheses, and uses thereof
WO2017004411A1 (en) 2015-07-01 2017-01-05 President And Fellows Of Harvard College Cortistatin analogues and syntheses and uses thereof
WO2017066697A1 (en) 2015-10-14 2017-04-20 Dou Qingping Treatments and diagnostics for cancers
IT201600083406A1 (it) * 2016-08-08 2018-02-08 Ind Chimica Srl PROCESSO PER LA PREPARAZIONE DI 3β-IDROSSI-17-(1H-BENZIMIDAZOL-1-IL)ANDROSTA-5,16-DIENE
IT201600121375A1 (it) * 2016-11-30 2018-05-30 Ind Chimica Srl PROCESSO PER LA PREPARAZIONE DI 3ß-IDROSSI-17-(1H-BENZIMIDAZOL-1-IL)ANDROSTA-5,16-DIENE
WO2018029223A1 (en) * 2016-08-08 2018-02-15 Industriale Chimica S.R.L. PROCESS FOR THE PREPARATION OF 3ß-HYDROXY-17-(1H-BENZIMIDAZOL-1-YL)ANDROSTA-5,16-DIENE
WO2019160889A1 (en) * 2018-02-13 2019-08-22 Dana-Farber Cancer Institute, Inc. Cyclin-dependent kinase inhibitors and methods of use
EP3752517A4 (en) * 2018-02-13 2021-10-13 Dana-Farber Cancer Institute, Inc. CYCLINE DEPENDENT KINASE DEGRADATION AGENTS AND METHODS OF USE

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA27440A (en) 1887-08-16 James T. Walsh Art of making sheet metal cans, for packing meats, fruits, vegetables, etc.
CH621803A5 (pl) * 1974-08-08 1981-02-27 Siphar Sa
US5604213A (en) 1992-03-31 1997-02-18 British Technology Group Limited 17-substituted steroids useful in cancer treatment
US5994335A (en) * 1997-10-17 1999-11-30 The University Of Maryland, Baltimore 17-azolyl steroids useful as androgen synthesis inhibitors
AU2004262909B2 (en) 2003-07-29 2010-07-01 Dompe' S.P.A. Pharmaceutical combination of G-CSF and PlGF useful for blood stem cell
DK2206719T3 (en) * 2005-03-02 2015-01-26 Univ Maryland A pharmaceutical composition comprising 3-BETA-HYDROXY-17- (1-H-benzimidazol-1-yl) androsta-5, 16-DIEN

Also Published As

Publication number Publication date
AU2006218711A2 (en) 2006-09-08
KR101380959B1 (ko) 2014-04-04
PT2206719E (pt) 2015-02-05
EP2206719A3 (en) 2011-01-05
JP5130453B2 (ja) 2013-01-30
CA2599953C (en) 2013-08-13
IL185608A (en) 2016-06-30
DK2206719T3 (en) 2015-01-26
US7875599B2 (en) 2011-01-25
IL210478A0 (en) 2011-03-31
HK1115387A1 (pl) 2008-11-28
AU2006218711A1 (en) 2006-09-08
JP5613206B2 (ja) 2014-10-22
CA2599953A1 (en) 2006-09-08
JP2008536807A (ja) 2008-09-11
BRPI0607523A2 (pt) 2009-09-08
US20080280864A1 (en) 2008-11-13
DE602006017175D1 (de) 2010-11-11
IL185608A0 (en) 2008-01-06
AU2006218711B2 (en) 2010-11-11
KR20070120119A (ko) 2007-12-21
DK1853619T3 (da) 2011-01-10
CN103349664A (zh) 2013-10-16
PT1853619E (pt) 2011-01-03
EP1853619A4 (en) 2009-08-26
WO2006093993A1 (en) 2006-09-08
ES2528055T3 (es) 2015-02-03
IL210480A0 (en) 2011-03-31
IL210480A (en) 2015-06-30
SI1853619T1 (sl) 2011-01-31
MX2007010593A (es) 2008-02-20
ES2353413T3 (es) 2011-03-01
SI2206719T1 (sl) 2015-03-31
NZ561571A (en) 2009-09-25
ATE482969T1 (de) 2010-10-15
CN101155823A (zh) 2008-04-02
EP2206719B1 (en) 2014-10-22
EP1853619B1 (en) 2010-09-29
EP2206719A2 (en) 2010-07-14
ZA200708106B (en) 2008-12-31
PL1853619T3 (pl) 2011-03-31
EP1853619A1 (en) 2007-11-14
EA200701872A1 (ru) 2008-06-30
EA019560B1 (ru) 2014-04-30
JP2012255026A (ja) 2012-12-27

Similar Documents

Publication Publication Date Title
PL2206719T3 (pl) Kompozycja farmaceutyczna zawierająca 3-beta-hydroksy-17-(1-h-benzimidazol-1-il)androsta-5,16-dien
HUS1600021I1 (hu) MEK inhibitorok és módszerek azok felhasználására
HK1061354A1 (en) Synthesis of 4-amino-thalidomide enantiomers
EP2966065A3 (en) Hydroxylated and methoxylated cyclopenta [d] pyrimidines as akt protein kinase inhibitors
WO2007087548A3 (en) Chemical compounds
MXPA06009475A (es) Derivados de quinazolina y usos terapeuticos de los mismos.
TW200833695A (en) Use of spiro-oxindole compounds as therapeutic agents
WO2009120565A3 (en) Novel prodrugs of c-17-heteroaryl steroidal cyp17 inhibitors/antiandrogens: synthesis, in vitro biological activities, pharmacokinetics and antitumor activity
EP2044961A3 (en) Phospholipid analogues for the treatment of cancers
WO2005077968A8 (en) 17-methylene-or 17 - spiro - cyclopropane 7 - substituted estra - 1, 3, 5 (10) - triene derivatives with anti - estrogenic activity
NO20076319L (no) Farmasoytiske sammensetninger av et neuroaktivt steroid og anvendelse derav
WO2005103010A3 (en) Pyrazole derivatives useful for the treatment of cancer
WO2008011539A3 (en) Anesthetic compounds
CY1115910T1 (el) ΦΑΡΜΑΚΕΥΤΙΚΗ ΣΥΝΘΕΣΗ ΠΟΥ ΠΕΡΙΛΑΜΒΑΝΕΙ 3-BETA-HYDROXY-17-(l-HBENZIMIDAZOLE-1-YL)ANDROSΤΑ-5,16-DIENE
TW200603812A (en) D-homo-17-chlor-16(17)-ene steroids
TW200740442A (en) Therapeutic agent for hypertension